Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTeva Pharma Industries Ltd ADR

Teva Pharma Industries Ltd ADR

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
41.575 USD -0.28 ( 0.66%)
Last update at 2026-11-05T18:00:00Z
VOLUME
8391497
Market Cap
45737.87M
P/E
65.42

Momentum Score

…

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
40.92
Low
42.38
High
52 Week Price Range
18.21
Low
39.49
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Teva Pharmaceutical Industries is a global drugmaker that develops and sells generic medicines alongside specialty products for conditions such as multiple sclerosis and movement disorders. Long-term growth could come from generic scale, emerging-market expansion, specialty drugs and biosimilars, and cost programs, and investors may view the firm as a diversified producer with potential for steady cash generation.

Material risks include intense generic pricing pressure, high leverage and significant legacy legal exposure, plus execution risk shifting toward higher-margin specialty and biosimilar lines.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
41.85
Dividend Yield
-
Revenue TTM
17315.00M
Revenue Per Share
15.00
Gross Profit TTM
9083.00M
Debt / Equity
2.20
ROE
9.69%
Net Debt
13825.79M
ROCE
7.84%
Diluted EPS TTM
0.60

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1238.00M -1283.00M -624.00M -3065.00M 658.00M
Minority interest -7.00M 320.00M 56.00M 53.00M 39.00M
Net income 1410.00M -1639.00M -559.00M -2353.00M 417.00M
Selling general administrative 1287.00M 1161.00M 1162.00M 1180.00M 1099.00M
Selling and marketing expenses 2686.00M 2541.00M 2336.00M 2265.00M 2429.00M
Gross profit 8938.00M 8063.00M 7645.00M 6973.00M 7594.00M
Reconciled depreciation 1002.00M 1059.00M 1153.00M 1308.00M 1330.00M
Ebit 2139.00M 3372.00M 433.00M 2797.00M 3198.00M
Ebitda 3141.00M 4431.00M 433.00M 4105.00M 4528.00M
Depreciation and amortization 1002.00M 1059.00M 1153.00M 1308.00M 1330.00M
Non operating income net other - - - - -1049.00M
Operating income 2157.00M -303.00M 433.00M 2797.00M 3198.00M
Other operating expenses 15100.00M 16847.00M 12652.00M 12235.00M 12779.00M
Interest expense 916.00M 941.00M 1029.00M 966.00M 1058.00M
Tax provision -180.00M 676.00M -7.00M -638.00M 211.00M
Net interest income -985.00M -1050.00M -1095.00M -966.00M -962.00M
Income tax expense -180.00M 676.00M -65.00M -638.00M 211.00M
Total revenue 17257.00M 16544.00M 15846.00M 14925.00M 15878.00M
Total operating expenses 6780.00M 8366.00M 4451.00M 4283.00M 4495.00M
Cost of revenue 8320.00M 8481.00M 8201.00M 7952.00M 8284.00M
Total other income expense net -919.00M -980.00M -1057.00M -5862.00M -2540.00M
Net income from continuing ops 1418.00M -1959.00M -615.00M -2406.00M 447.00M
Net income applicable to common shares - - - -2353.00M 417.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 40747.37M 39326.00M 43479.00M 44006.00M 47666.00M
Intangible assets 3780.94M 4418.00M 5387.00M 6270.00M 7466.00M
Other current assets 3501.95M 3186.00M 1830.00M 549.00M 967.00M
Total liab 32833.49M 33606.00M 35353.00M 35315.00M 36422.00M
Total stockholder equity 7909.88M 5373.00M 7506.00M 7897.00M 10278.00M
Other current liab 9104.86M 8812.00M 7973.00M 6020.00M 903.00M
Common stock 58.00M 58.00M 57.00M 57.00M 57.00M
Capital stock 58.00M 58.00M 57.00M 57.00M 57.00M
Retained earnings -13762.00M -15173.00M -13534.00M -12882.00M -10529.00M
Other liab - - - 4394.00M 3362.00M
Good will 15999.75M 15147.00M 17177.00M 17633.00M 20040.00M
Other assets - - 1.00M 1894.00M -1.00M
Cash 3555.95M 3300.00M 3226.00M 2801.00M 2165.00M
Total current liabilities 13455.79M 12796.00M 12247.00M 11469.00M 11027.00M
Current deferred revenue - - 4914.00M 1453.00M 7012.00M
Net debt 13825.79M 14779.00M 16927.00M 18760.00M 21294.00M
Short term debt 1819.97M 1781.00M 1672.00M 2109.00M 1426.00M
Short long term debt 1820.00M 1781.00M 1672.00M 2109.00M 1426.00M
Short long term debt total 17381.73M 18079.00M 20153.00M 21561.00M 23459.00M
Other stockholder equity 24005.06M 23636.00M 23680.00M 23560.00M 23433.00M
Property plant equipment - - - 6158.00M 5982.00M
Total current assets 13945.78M 12552.00M 12485.00M 12051.00M 12573.00M
Net tangible assets - - - -16006.00M -17228.00M
Net receivables 3708.94M 3059.00M 3408.00M 3696.00M 4529.00M
Long term debt 14986.00M 16002.00M 18161.00M 19103.00M 21617.00M
Inventory 3178.95M 3007.00M 4021.00M 3833.00M 3818.00M
Accounts payable 2530.96M 2203.00M 2602.00M 1887.00M 1686.00M
Noncontrolling interest in consolidated entity - - - - 966.00M
Accumulated other comprehensive income -2391.00M -3148.00M -2697.00M -2838.00M -2683.00M
Common stock total equity - - - - 57.00M
Retained earnings total equity - - - - -10529.00M
Treasury stock - - - - -4128.00M
Non currrent assets other 404.99M 462.00M 462.00M 441.00M 515.00M
Non current assets total 26801.58M 26774.00M 30993.00M 31955.00M 35094.00M
Capital lease obligations 288.00M 296.00M 320.00M 349.00M 416.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -15.00M 792.00M 968.00M 656.00M 172.00M
Change to liabilities - - - 1914.00M 764.00M
Total cashflows from investing activities 737.00M 792.00M 968.00M 656.00M 1523.00M
Net borrowings -1814.00M -1641.00M -1701.00M -1369.00M -1675.00M
Total cash from financing activities -2151.00M -1791.00M -1913.00M -1487.00M -2172.00M
Change to operating activities - - - -828.00M -1701.00M
Net income 1418.00M -1959.00M -615.00M -2406.00M 456.00M
Change in cash 256.00M 73.00M 393.00M 636.00M 21.00M
Begin period cash flow 3300.00M 3227.00M 2834.00M 2198.00M 2177.00M
End period cash flow 3556.00M 3300.00M 3227.00M 2834.00M 2198.00M
Total cash from operating activities 1649.00M 1247.00M 1368.00M 1590.00M 798.00M
Depreciation 1002.00M 1059.00M 1153.00M 1308.00M 1330.00M
Other cashflows from investing activities 1219.00M 1293.00M 1472.00M - 1913.00M
Change to inventory 152.00M 166.00M -147.00M -163.00M 380.00M
Change to account receivables -173.00M 245.00M 12.00M 334.00M -574.00M
Other cashflows from financing activities -337.00M -150.00M -212.00M -118.00M 5668.00M
Change to netincome - - - 1378.00M 729.00M
Capital expenditures 501.00M 498.00M 526.00M 548.00M 562.00M
Cash flows other operating - - - - -3988.00M
Cash and cash equivalents changes - - - - 149.00M
Change in working capital -1366.00M -435.00M -72.00M 1257.00M -1701.00M
Stock based compensation 157.00M 123.00M 121.00M 124.00M 119.00M
Other non cash items 1109.00M 3093.00M 1098.00M 2366.00M 714.00M
Free cash flow 1148.00M 749.00M 842.00M 1042.00M 236.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TEVA
Teva Pharma Industries Ltd ADR		 -0.28
0.66%		 41.58 65.42 12.55 2.64 5.82 3.35 18.43
MKKGY
Merck KGaA ADR		 -0.44
1.29%		 33.62 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.43
1.43%		 167.57 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.33
1.54%		 21.39 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.01
0.01%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Teva Pharma Industries Ltd ADR

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

124 Dvora HaNevi?a St., Tel Aviv-Yafo, Israel, 6944020

972 3 914 8213

https://www.tevapharm.com

31173

Name Title Year Born
Mr. Kare Schultz Pres, CEO & Director 1961
Mr. Eliyahu Sharon Kalif Exec. VP & CFO 1973
Mr. Eric Drape Exec. VP of Global Operations 1962
Mr. Mark Sabag Exec. VP of International Markets Commercial 1971
Dr. Sven Dethlefs Ph.D. Exec. VP of North America Commercial 1969
Mr. Amir Weiss Sr. VP & Chief Accounting Officer 1977
Mr. Kevin C. Mannix Sr. VP of Investor Relations NA
Mr. David M. Stark Exec. VP & Chief Legal Officer 1969
Kathleen Veit Sr. VP, Global Compliance & Ethics Officer NA
Mr. Eli Shani Exec. VP of Global Marketing & Portfolio NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

LIF
CAD 21.93
+8.08%
CRON
CAD 5.29
+7.30%
CIA
CAD 2.05
+6.77%
THX
CAD 0.97
+5.43%
OGC
CAD 37.98
+5.38%
GIL
CAD 46.87
-22.45%
IFOS
CAD 1.70
-20.56%
ITH
CAD 1.99
-18.65%
KEEL
CAD 2.41
-17.75%
TNZ
CAD 51.05
-17.39%

Equity Sectors*

  • No sector data available

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…